Why the study?
What are the pharmacokinetic and toxicity profiles of pegylated liposomal doxorubicin compared to free doxorubicin in women with epithelial ovarian cancer?
What are the pharmacokinetic and toxicity profiles of pegylated liposomal doxorubicin compared to free doxorubicin in women with epithelial ovarian cancer?
Pegylated liposomal doxorubicin offers a favorable pharmacokinetic and toxicity profile, including reduced cardiotoxicity, making it a viable option for first- and second-line treatment of ovarian cancer.
Answers are grounded in this paper and cite their sources.
Supports PLD consideration in ovarian cancer for lower cardiotoxicity; leaves open prospective RCT confirmation before practice change.
INTRODUCTION: Safe and effective treatments are needed for ovarian cancer. While there are many drugs currently available, there has recently been a renewed novel interest in the use of anthracyclines. AREAS COVERED: This review summarizes the available evidence on pharmacokinetic (PK) and toxicology implications of anthracyclines and pegylated liposomal doxorubicin (PLD) in the clinical management of women with epithelial ovarian cancer. This article consists of material obtained via Medline, PubMed and EMBASE literature searches, up to September 2010. EXPERT OPINION: PLD is a liposomal formulation of doxorubicin (DXR), with a distinct pharmacokinetic profile, characterized by extended circulation time and a reduced clearance and volume of distribution with respect to the free drug. PLD is effective and well tolerated in relapsed ovarian cancer. The toxicity profile of PLD is characterized by dose-limiting mucosal and cutaneous toxicities, mild myelosuppression and decreased cardiotoxicity compared to free DXR. The good response rate, toxicity profile and pharmacokinetic profile of PLD suggest that PLD could be an option in first-line and second-line treatment in ovarian cancer; especially in those who had experienced taxane-induced toxicity or had a poor performance status.
No takes yet. Share an insight, caveat, or question.
Morotti et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: